SCHEMBL20595835

SCHEMBL20595835

COc1ccc(-c2ccc(N)c3nc(CC(=O)Nc4ccc(Cl)nc4N)cn23)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ LMNA P02545 2/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CA12 O43570 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ SCN10A Q9Y5Y9 2/20 0.35
▸ HSP90AA1 P07900 1/20 0.35
▸ HSP90AB1 P08238 1/20 0.35
▸ NOD2 Q9HC29 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ SCN1A P35498 1/20 0.34
▸ SCN5A Q14524 1/20 0.34
▸ SCN9A Q15858 1/20 0.34
▸ USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20596051 0.90 CA12 (0.37) MEN1MAPK1KMT2ALMNAALDH1A1
SCHEMBL23419542 0.88 CYP2C8 (0.36) —
SCHEMBL20596490 0.86 MARS2 (0.42) MEN1MAPK1KMT2ALMNAALDH1A1
SCHEMBL20596538 0.84 LMNA (0.38) MEN1MAPK1KMT2ALMNAALDH1A1
SCHEMBL20596076 0.84 NOD2 (0.38) MEN1MAPK1KMT2ALMNAALDH1A1
SCHEMBL20596077 0.84 HSP90AA1 (0.39) MEN1KMT2ALMNAALDH1A1SCN10A
SCHEMBL20596534 0.81 LMNA (0.39) MEN1MAPK1KMT2ALMNAALDH1A1
SCHEMBL20595923 0.81 CYP1A2 (0.39) MEN1MAPK1KMT2ALMNAALDH1A1
SCHEMBL20596510 0.80 LMNA (0.36) MEN1MAPK1KMT2ALMNAALDH1A1
SCHEMBL23419543 0.79 LMNA (0.36) MEN1KMT2ALMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 MEN1 1598/4885MAPK1 4114/4885KMT2A 1475/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR MEN1 2393/4885MAPK1 4685/4885KMT2A 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback